A Randomized, Double-Blind Clinical Trial to Determine the Efficacy of Imidapril vs. Enalapril in Patients with Stage 1 to 2 Essential Hypertension.
10.4070/kcj.1999.29.11.1234
- Author:
Young Jin CHOI
;
Dae Won SOHN
;
Yong Jin KIM
;
Hong Ja LEE
;
In Ho CHAE
;
Hyo Soo KIM
;
Cheol Ho KIM
;
Byung Hee OH
;
Myoung Mook LEE
;
Young Bae PARK
;
Yun Shik CHOI
;
Young Woo LEE
- Publication Type:Clinical Trial ; Randomized Controlled Trial ; Original Article
- Keywords:
Hypertension;
Imidapril
- MeSH:
Blood Pressure;
Enalapril*;
Heart Rate;
Humans;
Hypertension*;
Peptidyl-Dipeptidase A
- From:Korean Circulation Journal
1999;29(11):1234-1239
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Imidapril is a long-acting angiotensin converting enzyme inhibitor, which has been demons-trated to be effective in reducing blood pressure. The purpose of this study is to compare the antihypertensive efficacy, safety and tolerability of imidapril and enalapril in patients with stage 1 to 2 essential hypertension. METHODS: In this double-blind, double-dummy, randomized, parallel study, the efficacy, safety and tolerability of once-daily imidapril versus once-daily enalapril were evaluated in 84 patients with stage 1 - 2 hypertension during 8 weeks. If antihypertensive response was insufficient after 4 week treatment period, the dosage for both study drugs doubled until the end of study. RESULTS: Data from 84 patients who completed the study were eligible for per-protocol analysis. An adequate antihypertensive effect was observed in 47.6% (20/42) in the imidapril group and in 23.8% (10/42) in enalapril group. There was statistically significant difference between the two treatments in the percentage of patients achieving a "reduced blood pressure". The pulse rate did not changed in both groups. Safety profiles were similar between treatments. CONCLUSION: In patients with mild to moderate hypertension, the imidapril group showed better response with regard to antihypertensive effect. Both imidapril and enalapril were well tolerated with similar safety profiles.
